Search research articles
Contact Us
Filters
Showing results (1-10 of 37) with videos related to
Page
of 4
Sort By:
Contemporary Clinical Trials
|
September 14, 2010
Adjusted significance levels for subgroup analyses in clinical trials
Bart Spiessens, Muriel Debois
Statistics in Medicine
|
February 19, 2003
A comparison of group sequential methods for binary longitudinal data
Bart Spiessens, Emmanuel Lesaffre, Geert Verbeke
Biometrics
|
September 17, 2002
Group sequential methods for an ordinal logistic random-effects model under misspecification
Bart Spiessens, Emmanuel Lesaffre, Geert Verbeke, et al.
Statistics in Medicine
|
October 13, 2005
Tutorial in biostatistics: the self-controlled case series method
Heather J Whitaker, C Paddy Farrington, Bart Spiessens, et al.
BMC Infectious Diseases
|
August 8, 2024
Unbiased identification of risk factors for invasive Escherichia coli disease using machine learning
Erik Clarke, Christel Chehoud, Najat Khan, et al.
Biometrical Journal. Biometrische Zeitschrift
|
October 21, 2016
Testing interaction between treatment and high-dimensional covariates in randomized clinical trials
Andrea Callegaro, Bart Spiessens, Benjamin Dizier, et al.
Human Vaccines
|
February 18, 2009
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials
Dominique Descamps, Karin Hardt, Bart Spiessens, et al.
Expert Review of Vaccines
|
September 26, 2023
Harmonizing the collection of solicited adverse events in prophylactic vaccine clinical trials
Brigitte Cheuvart, Bart Spiessens, Roy van Heesbeen, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
|
September 7, 2024
Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60-85 years in a randomized, double-blind, phase 1 study
Miwa Haranaka, Atsushi Momose, Yoshikazu Nakayama, et al.
Vaccine
|
June 21, 2020
Characterization of Escherichia coli isolates potentially covered by ExPEC4V and ExPEC10V, that were collected from post-transrectal ultrasound-guided prostate needle biopsy invasive urinary tract and bloodstream infections
Elie Saade, Stefan Gravenstein, Curtis J Donskey, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 37) with videos related to
Sort By:
Page
of 4
Contemporary Clinical Trials
|
September 14, 2010
Adjusted significance levels for subgroup analyses in clinical trials
Bart Spiessens, Muriel Debois
Statistics in Medicine
|
February 19, 2003
A comparison of group sequential methods for binary longitudinal data
Bart Spiessens, Emmanuel Lesaffre, Geert Verbeke
Biometrics
|
September 17, 2002
Group sequential methods for an ordinal logistic random-effects model under misspecification
Bart Spiessens, Emmanuel Lesaffre, Geert Verbeke, et al.
Statistics in Medicine
|
October 13, 2005
Tutorial in biostatistics: the self-controlled case series method
Heather J Whitaker, C Paddy Farrington, Bart Spiessens, et al.
BMC Infectious Diseases
|
August 8, 2024
Unbiased identification of risk factors for invasive Escherichia coli disease using machine learning
Erik Clarke, Christel Chehoud, Najat Khan, et al.
Biometrical Journal. Biometrische Zeitschrift
|
October 21, 2016
Testing interaction between treatment and high-dimensional covariates in randomized clinical trials
Andrea Callegaro, Bart Spiessens, Benjamin Dizier, et al.
Human Vaccines
|
February 18, 2009
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials
Dominique Descamps, Karin Hardt, Bart Spiessens, et al.
Expert Review of Vaccines
|
September 26, 2023
Harmonizing the collection of solicited adverse events in prophylactic vaccine clinical trials
Brigitte Cheuvart, Bart Spiessens, Roy van Heesbeen, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
|
September 7, 2024
Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60-85 years in a randomized, double-blind, phase 1 study
Miwa Haranaka, Atsushi Momose, Yoshikazu Nakayama, et al.
Vaccine
|
June 21, 2020
Characterization of Escherichia coli isolates potentially covered by ExPEC4V and ExPEC10V, that were collected from post-transrectal ultrasound-guided prostate needle biopsy invasive urinary tract and bloodstream infections
Elie Saade, Stefan Gravenstein, Curtis J Donskey, et al.
Page
of 4